Hepatitis C, HIV-1 Infection
Conditions
Brief summary
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with sofosbuvir-containing therapy does not work. It is not known if people respond to retreatment with sofosbuvir, after it did not work the first time. There is an important need to understand retreatment options in those instances. This clinical trial was done to study the response to two different regimens, ledipasvir/sofosbuvir and ledipasvir/sofosbuvir with ribavirin, and to see if they are safe and well-tolerated in HCV-infected persons whose previous treatment with sofosbuvir had failed.
Detailed description
There is a pressing need to understand appropriate retreatment options for HCV-infected patients who fail direct acting antiviral (DAA)-based regimens. To date, over 100,000 prescriptions have been written for SOF. Recent data indicate that SOF-based treatment defined as SOF/RBV, SOF/pegylated-interferon (PEG-IFN)/RBV or SOF/simeprevir (SIM) +/- RBV have led to treatment response of 70-92% in HCV genotype (GT) 1 patients, depending on the regimen used and presence of liver cirrhosis. Thus, there is a growing number of individuals who have failed SOF-based regimens and are in need of a retreatment strategy, the majority of which are anticipated to be HCV GT1, given the US distribution of genotypes. There are no data to inform retreatment strategies for HIV-infected individuals with SOF failure, who have traditionally represented a harder to treat group and are impacted by DAA-antiretroviral (ARV) interactions. This was a phase II retreatment study of HCV GT1 and HIV coinfected participants who had previous HCV virologic failure on a SOF-based regimen. Participants were randomized to one of two treatment arms: 12 weeks of LDV/SOF with weight-based RBV (Arm A) or 24 weeks of LDV/SOF alone (Arm B). The targeted sample size was 40, 20 participants in each arm. Post-entry, the study visits were scheduled at weeks 1, 2, 4, 8, 12, 16, 20 and 24 after study entry (with week 16, 20, 24 visits limited to those on the 24-week regimen), and at 4, 12 and 24 weeks after treatment discontinuation. The total study duration was 36 weeks in Arm A and 48 weeks in Arm B. At each visit, a physical examination and blood collection were conducted. HCV RNA was tested at each visit. For female participants of reproductive potential, pregnancy tests were done. At on-treatment visits, participants also completed an HCV treatment adherence questionnaire. Urinalysis was conducted at all on-treatment visits and at 4 weeks post treatment. At select visits, plasma, whole blood, urine and dried blood spots were collected. The study was randomized because there was clinical equipoise on the benefits and drawbacks in the two study arms. The study was not designed to be powered for comparisons between the randomized study arms, and no formal statistical comparisons were conducted. The primary analysis was conducted as a single-arm analysis for each regimen. The study experienced enrollment difficulties due to the small number of HCV treatment failures from select SOF-based regimens who would be eligible for this study, and closed to accrual prematurely. The participants enrolled remained on study until completion of follow-up.
Interventions
Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
DRUGRibavirin
Based on weight at entry: For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally. For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide written informed consent * Documentation of non-cirrhotic or cirrhotic status * HIV-1 infection * HIV antiretroviral treatment status (ART), CD4+ T-cell (CD4) count and HIV-1 RNA as follows: (1) not on ART with CD4 count \>500 cells/mm\^3 within 42 days of study entry, (2) elite controller not on ART with CD4 \>200 cells/mm\^3 within 42 days of study entry and HIV-1 RNA \<500 copies/mL on all measurements within 48 weeks prior to study entry, (3) on a stable protocol-approved ART with CD4 count \>200 cells/mm\^3 and HIV-1 RNA \<50 copies/mL within 42 days of study entry * HCV GT-1 within 12 months prior to study entry * Prior virologic treatment failure with SOF-containing regimen (SOF/RBV, SOF/PEG/RBV, and SOF/SIM) * Body mass index (BMI) ≥18 kg/m\^2 within 42 days prior to study entry * Certain laboratory values obtained within 42 days prior to study entry * Hemoglobin ≥12.0 g/dL for male, ≥11.0 g/dL for female participants * Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGOT) \<10 x ULN * For female participants of reproductive potential, a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL performed at screening and within 48 hours prior to study entry * Agreement to use at least two reliable forms of contraceptive simultaneously while receiving study treatment and for 6 months afterward * Intention to comply with the dosing instructions and study schedule of assessments
Exclusion criteria
* Receipt of any investigational drug or device within 60 days prior to study entry * Prior exposure to a DAA other than SOF and SIM * Chronic liver disease of a non-HCV etiology * Presence of active or acute AIDS-defining opportunistic infections within 42 days prior to study entry * Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals within 42 days prior to study entry * Hepatitis B virus (HBV) infection (defined as HBsAg positive) within 42 days prior to study entry * History of clinically significant hemoglobinopathy * Chronic current use of systemically administered immunosuppressive agents * History of solid organ transplantation * Current or prior history of clinical hepatic decompensation * History of a gastrointestinal disorder (or postoperative condition) that could interfere with the absorption of the study drug * History of significant or symptomatic pulmonary disease, cardiac disease, or porphyria that in the opinion of the investigator would interfere with the study * History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy * Active drug or alcohol use or dependence * Use of any prohibited concomitant medications per the LDV/SOF product labeling, within 42 days prior to study entry * Known hypersensitivity to RBV, SOF, LDV, their metabolites, or formulation excipients or any other contraindication to the use of RBV, SOF or LDV * Currently receiving zidovudine (ZDV), didanosine (ddI), stavudine (d4T) or tipranavir * Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable * Known hepatocellular carcinoma * Breastfeeding or pregnancy * A male participant with a pregnant female partner * Receipt of colony stimulating agents, including but not limited to erythropoietin, within 42 days prior to study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | At 12 weeks after treatment discontinuation (i.e., at 24 weeks after study entry in Arm A and at 36 weeks after study entry in Arm B). | SVR12 was defined as HCV RNA below the LLOQ of the assay (either target detected \[TD\] or target not detected \[TND\]) at 12 weeks after treatment discontinuation. The sample within the visit window, closest to the targeted time was used. If there was no HCV RNA sample within visit window, then the participant was considered not to have achieved SVR12, unless there were preceding and subsequent HCV RNA measurements that were both \<LLOQ (either TD or TND). HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals. |
| Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | From study treatment initiation to 30 days after study treatment discontinuation. Duration of treatment was 12 weeks in Arm A and 24 weeks in Arm B. | Percentage of participants who experienced an AE (diagnosis, sign/symptom or laboratory abnormality) of ≥Grade 3, SAE according to International Conference on Harmonisation (ICH) criteria, or AE reported as the reason for permanent study treatment discontinuation, during study treatment and up to 30 days after study treatment. Events that were ongoing at the same grade from prior to study treatment initiation were excluded. AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (V2.0) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening. The percentage of participants who experienced any event (overall), and the percentage of participants who experienced each component of the outcome are provided in the data table below. The categories are not mutually exclusive. A participant may have experienced multiple events. Each participant is counted at most once within category, and in the overall summary line. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | At 24 weeks after treatment discontinuation (i.e., at 36 weeks after study entry in Arm A and at 48 weeks after study entry in Arm B). | SVR24 was defined as HCV RNA below the LLOQ of the assay (either TD or TND) at 24 weeks after treatment discontinuation. The sample from a visit greater than 20 weeks after treatment discontinuation which was closest to the targeted week (24 weeks post treatment), not followed by any HCV RNA result ≥LLOQ, was used. If there was no HCV RNA sample within this window, then the participant was considered not to have achieved SVR24. HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals. |
| Number of Participants With Unquantifiable HCV RNA | Entry (Week 0); at 1, 4, 8, 12 (and 16, 20, 24 in Arm B) weeks after study entry | Unquantifiable HCV was defined as HCV RNA below the LLOQ of the assay (15 IU/mL), either TD or TND. HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). |
| Percentage of Participants With Protocol-specified Renal Events | From study entry to study completion (Week 36 in Arm A, Week 48 in Arm B) | The study protocol defined renal events as (1) ≥Grade 2 creatinine clearance (CRCL) after study entry, or (2) new urinalysis proteinuria and/or glucosuria, defined as ≥1+ or an increase ≥1+ from baseline. The percentage of participants who experienced any renal event, and the percentages of participants who experienced each component of the outcome are provided in the data table below. The categories are not mutually exclusive. A participant may have experienced multiple events. Each participant is counted at most once within category, and in the overall summary line. |
| CD4+ T-cell (CD4) Count Change From Baseline | Entry and at 12 (and 24 in Arm B) weeks after study entry | Change in CD4 count was calculated as value at the post entry visit minus the value at study entry. |
| Number of Participants With HIV-1 RNA >50 Copies/mL | Entry (Week 0); at 4, 12 (and 24 in Arm B) weeks after study entry, and at 4 weeks after treatment discontinuation | HIV-1 RNA testing was performed at a central laboratory using Abbott RealTime HIV-1 assay (Abbott Laboratories, Lake Bluff, IL, USA). |
| Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4) | At 4 weeks after treatment discontinuation (i.e., at 16 weeks after study entry in Arm A and at 28 weeks after study entry in Arm B). | SVR4 was defined as HCV RNA below the LLOQ of the assay (either TD or TND) at 4 weeks after treatment discontinuation. The sample within the visit window, closest to the targeted time was used. If there was no HCV RNA sample within visit window, then the participant was considered not to have achieved SVR4, unless there were preceding and subsequent HCV RNA measurements that were both \<LLOQ (either TD or TND). HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals. |
Countries
United States
Participant flow
Recruitment details
Participants were enrolled from February to June 2016 at 3 U.S. sites.
Participants by arm
| Arm | Count |
|---|---|
| Arm A: LDV/SOF + RBV Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up. | 4 |
| Arm B: LDV/SOF Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up. | 3 |
| Total | 7 |
Baseline characteristics
| Characteristic | Arm A: LDV/SOF + RBV | Arm B: LDV/SOF | Total |
|---|---|---|---|
| Age, Continuous | 52 years | 58 years | 53 years |
| CD4+ T-cell count | 564 cells/mm^3 | 387 cells/mm^3 | 528 cells/mm^3 |
| Cirrhosis status Cirrhotic | 1 Participants | 0 Participants | 1 Participants |
| Cirrhosis status Non-cirrhotic | 3 Participants | 3 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| HCV genotype 1A | 2 Participants | 3 Participants | 5 Participants |
| HCV genotype 1B | 2 Participants | 0 Participants | 2 Participants |
| HCV RNA | 6.31 log10 IU/mL | 7.01 log10 IU/mL | 6.71 log10 IU/mL |
| HIV-1 RNA quantitation Quantifiable | 0 Participants | 0 Participants | 0 Participants |
| HIV-1 RNA quantitation Unquantifiable | 4 Participants | 3 Participants | 7 Participants |
| HIV antiretroviral treatment (ART) status Not on ART | 0 Participants | 0 Participants | 0 Participants |
| HIV antiretroviral treatment (ART) status On ART | 4 Participants | 3 Participants | 7 Participants |
| Intravenous drug use history Never | 2 Participants | 3 Participants | 5 Participants |
| Intravenous drug use history Previously | 2 Participants | 0 Participants | 2 Participants |
| Prior hepatitis C virus (HCV) treatment regimen SOF/RBV | 2 Participants | 1 Participants | 3 Participants |
| Prior hepatitis C virus (HCV) treatment regimen SOF/RBV/PEG-IFN | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 1 Participants | 4 Participants |
| Region of Enrollment United States | 4 Participants | 3 Participants | 7 Participants |
| Sex: Female, Male Female | 0 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Male | 4 Participants | 1 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 3 |
| other Total, other adverse events | 2 / 4 | 3 / 3 |
| serious Total, serious adverse events | 0 / 4 | 0 / 3 |
Outcome results
Primary
Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment
Percentage of participants who experienced an AE (diagnosis, sign/symptom or laboratory abnormality) of ≥Grade 3, SAE according to International Conference on Harmonisation (ICH) criteria, or AE reported as the reason for permanent study treatment discontinuation, during study treatment and up to 30 days after study treatment. Events that were ongoing at the same grade from prior to study treatment initiation were excluded. AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (V2.0) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening. The percentage of participants who experienced any event (overall), and the percentage of participants who experienced each component of the outcome are provided in the data table below. The categories are not mutually exclusive. A participant may have experienced multiple events. Each participant is counted at most once within category, and in the overall summary line.
Time frame: From study treatment initiation to 30 days after study treatment discontinuation. Duration of treatment was 12 weeks in Arm A and 24 weeks in Arm B.
Population: All participants enrolled.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Overall (any event) | 50.0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Diagnosis ≥ Grade 3 | 0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Laboratory event ≥ Grade 3 | 50.0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Sign/symptom ≥ Grade 3 | 0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | SAE | 0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | AE that led to treatment discontinuation | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | SAE | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Overall (any event) | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Sign/symptom ≥ Grade 3 | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Diagnosis ≥ Grade 3 | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | AE that led to treatment discontinuation | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment | Laboratory event ≥ Grade 3 | 0 percentage of participants |
Primary
Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
SVR12 was defined as HCV RNA below the LLOQ of the assay (either target detected \[TD\] or target not detected \[TND\]) at 12 weeks after treatment discontinuation. The sample within the visit window, closest to the targeted time was used. If there was no HCV RNA sample within visit window, then the participant was considered not to have achieved SVR12, unless there were preceding and subsequent HCV RNA measurements that were both \<LLOQ (either TD or TND). HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals.
Time frame: At 12 weeks after treatment discontinuation (i.e., at 24 weeks after study entry in Arm A and at 36 weeks after study entry in Arm B).
Population: All participants enrolled.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: LDV/SOF + RBV | Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | 100.0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | 100.0 percentage of participants |
Secondary
CD4+ T-cell (CD4) Count Change From Baseline
Change in CD4 count was calculated as value at the post entry visit minus the value at study entry.
Time frame: Entry and at 12 (and 24 in Arm B) weeks after study entry
Population: All participants enrolled with CD4 result available at entry and at the post-entry visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Arm A: LDV/SOF + RBV | CD4+ T-cell (CD4) Count Change From Baseline | Week 12: CD4 change | -102 cells/mm^3 |
| Arm B: LDV/SOF | CD4+ T-cell (CD4) Count Change From Baseline | Week 12: CD4 change | 365 cells/mm^3 |
| Arm B: LDV/SOF | CD4+ T-cell (CD4) Count Change From Baseline | Week 24: CD4 change | 138 cells/mm^3 |
Secondary
Number of Participants With HIV-1 RNA >50 Copies/mL
HIV-1 RNA testing was performed at a central laboratory using Abbott RealTime HIV-1 assay (Abbott Laboratories, Lake Bluff, IL, USA).
Time frame: Entry (Week 0); at 4, 12 (and 24 in Arm B) weeks after study entry, and at 4 weeks after treatment discontinuation
Population: All participants enrolled with HIV-1 RNA results available at the visit.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: LDV/SOF + RBV | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 12: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 0: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 4: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With HIV-1 RNA >50 Copies/mL | Post treatment Week 4: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With HIV-1 RNA >50 Copies/mL | Post treatment Week 4: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 4: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 12: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 24: HIV-1 RNA >50 copies/mL | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With HIV-1 RNA >50 Copies/mL | Week 0: HIV-1 RNA >50 copies/mL | 0 Participants |
Secondary
Number of Participants With Unquantifiable HCV RNA
Unquantifiable HCV was defined as HCV RNA below the LLOQ of the assay (15 IU/mL), either TD or TND. HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland).
Time frame: Entry (Week 0); at 1, 4, 8, 12 (and 16, 20, 24 in Arm B) weeks after study entry
Population: All participants enrolled who had HCV RNA results available at the visit.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm A: LDV/SOF + RBV | Number of Participants With Unquantifiable HCV RNA | Week 0: unquantifiable HCV RNA | 0 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With Unquantifiable HCV RNA | Week 1: unquantifiable HCV RNA | 1 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With Unquantifiable HCV RNA | Week 4: unquantifiable HCV RNA | 4 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With Unquantifiable HCV RNA | Week 8: unquantifiable HCV RNA | 4 Participants |
| Arm A: LDV/SOF + RBV | Number of Participants With Unquantifiable HCV RNA | Week 12: unquantifiable HCV RNA | 4 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 4: unquantifiable HCV RNA | 3 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 20: unquantifiable HCV RNA | 3 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 8: unquantifiable HCV RNA | 3 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 24: unquantifiable HCV RNA | 3 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 0: unquantifiable HCV RNA | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 12: unquantifiable HCV RNA | 2 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 1: unquantifiable HCV RNA | 0 Participants |
| Arm B: LDV/SOF | Number of Participants With Unquantifiable HCV RNA | Week 16: unquantifiable HCV RNA | 3 Participants |
Secondary
Percentage of Participants With Protocol-specified Renal Events
The study protocol defined renal events as (1) ≥Grade 2 creatinine clearance (CRCL) after study entry, or (2) new urinalysis proteinuria and/or glucosuria, defined as ≥1+ or an increase ≥1+ from baseline. The percentage of participants who experienced any renal event, and the percentages of participants who experienced each component of the outcome are provided in the data table below. The categories are not mutually exclusive. A participant may have experienced multiple events. Each participant is counted at most once within category, and in the overall summary line.
Time frame: From study entry to study completion (Week 36 in Arm A, Week 48 in Arm B)
Population: All participants enrolled.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A: LDV/SOF + RBV | Percentage of Participants With Protocol-specified Renal Events | Overall (any renal event) | 25.0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Protocol-specified Renal Events | CRCL ≥ Grade 2 | 25.0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Protocol-specified Renal Events | Proteinuria | 25.0 percentage of participants |
| Arm A: LDV/SOF + RBV | Percentage of Participants With Protocol-specified Renal Events | Glucosuria | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Protocol-specified Renal Events | Glucosuria | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Protocol-specified Renal Events | Overall (any renal event) | 33.3 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Protocol-specified Renal Events | Proteinuria | 0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Protocol-specified Renal Events | CRCL ≥ Grade 2 | 33.3 percentage of participants |
Secondary
Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
SVR24 was defined as HCV RNA below the LLOQ of the assay (either TD or TND) at 24 weeks after treatment discontinuation. The sample from a visit greater than 20 weeks after treatment discontinuation which was closest to the targeted week (24 weeks post treatment), not followed by any HCV RNA result ≥LLOQ, was used. If there was no HCV RNA sample within this window, then the participant was considered not to have achieved SVR24. HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals.
Time frame: At 24 weeks after treatment discontinuation (i.e., at 36 weeks after study entry in Arm A and at 48 weeks after study entry in Arm B).
Population: All participants enrolled.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: LDV/SOF + RBV | Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | 100.0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | 100.0 percentage of participants |
Secondary
Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4)
SVR4 was defined as HCV RNA below the LLOQ of the assay (either TD or TND) at 4 weeks after treatment discontinuation. The sample within the visit window, closest to the targeted time was used. If there was no HCV RNA sample within visit window, then the participant was considered not to have achieved SVR4, unless there were preceding and subsequent HCV RNA measurements that were both \<LLOQ (either TD or TND). HCV RNA testing was conducted at a central laboratory using the COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland). Wilson (score) method was used for confidence intervals.
Time frame: At 4 weeks after treatment discontinuation (i.e., at 16 weeks after study entry in Arm A and at 28 weeks after study entry in Arm B).
Population: All participants enrolled.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A: LDV/SOF + RBV | Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4) | 100.0 percentage of participants |
| Arm B: LDV/SOF | Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4) | 100.0 percentage of participants |